A continual reassessment method without undue risk of toxicity

Weijia Zhang, Xikui Wang*, Saman Muthukumarana, Po Yang

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


We revisit our earlier extension of the CRM and introduce a new version of the dose escalation procedure. Its performance is assessed by simulation, with respect to a template of five operating measures BEARS (Benchmark, Efficiency, Accuracy, Reliability, Safety) that was used in Zhang, Wang and Yang. Our goal is to correctly identify the maximum tolerated dose with a high probability while protecting trial subjects from undue risk of toxicity. Simulation results show that this may be achieved for some considered scenarios, selective models, and considered competing designs. We discuss the pros and cons of the new version of the dose escalation procedure in the face of treatment versus experimentation dilemma.

Original languageEnglish
Pages (from-to)1179-1191
Number of pages13
JournalCommunications in Statistics: Simulation and Computation
Issue number4
Publication statusPublished - 2023
Externally publishedYes


  • Bayesian method
  • Continual reassessment method
  • Dose finding
  • Maximum tolerated dose
  • Phase I clinical trials
  • Toxicity


Dive into the research topics of 'A continual reassessment method without undue risk of toxicity'. Together they form a unique fingerprint.

Cite this